Application of THRIVE in Burn Children With Suspected Difficult Airway
Launched by SHUXIU WANG · Jun 10, 2024
Trial Information
Current as of July 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new technique called THRIVE, which stands for transnasal humidified rapid-insufflation ventilatory exchange, to see if it can help children with burns in their head, face, or neck. The goal is to make it easier to insert a breathing tube (intubation) for these children, especially since they might have a difficult airway due to their injuries. Researchers want to find out if using THRIVE can help doctors successfully intubate these children on the first try without causing a drop in oxygen levels.
To participate in this study, children must be under 18 years old and have certain types of burns or injuries on their head, face, or neck. They should not have other serious health issues or injuries that would make the procedure too risky. If eligible, participants will receive anesthesia, then have a special nasal device placed in their nose to help keep their oxygen levels stable during the intubation process. The study aims to compare the success rates of the THRIVE technique with standard care to determine if it truly makes a difference in these challenging situations.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • \< 18 years
- • ASA Grade I \~ III
- • Children with head, face and neck scald or burn or flame or electrical c hemical or other
- Exclusion Criteria:
- • Refusal or failure to sign an informed consent
- • Proposed to transnasal intubation
- • Fracture of the nasal bone, nasal bleeding, nasal deformity or obstruction
- • Tracheotomy status or severe head, face and neck burn or burn scar (difficult airway)
- • Unsuitable for rapid sequence induction
- • Basicranial fracture
- • Cyanotic congenital heart defect
- • At risk of malignant hyperthermia
- • And is participating in other clinical studies
About Shuxiu Wang
Shuxiu Wang is a dedicated clinical trial sponsor committed to advancing medical research and enhancing patient care through innovative therapeutic solutions. With a focus on rigorous scientific methodology and ethical standards, Shuxiu Wang oversees a range of clinical studies aimed at evaluating the safety and efficacy of novel treatments across various therapeutic areas. By fostering collaboration among healthcare professionals, researchers, and regulatory bodies, Shuxiu Wang aims to contribute to the development of groundbreaking therapies that address unmet medical needs and improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
shuxiu wang, PH.D
Principal Investigator
The Xijing Hospital of Air Force Military Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported